MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer-Reference-Cited by-同舟云学术

MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer

Published:2016-09-26 Issue:3 Volume:17 Page:323-333
ISSN:1574-0153
Container-title:Cancer Biomarkers
language:
Short-container-title:CBM

Author:

Adam Julien¹²³¹,Sourisseau Tony²³¹,Olaussen Ken A.¹²³,Robin Angélique²³,Zhu Chang Q.⁴,Templier Alexandre⁵,Civet Alexandre⁵,Girard Philippe⁶,Lazar Vladimir²,Validire Pierre⁶⁷,Tsao Ming S.⁴,Soria Jean-Charles¹²³,Besse Benjamin¹²³

Affiliation:

1. Univ Paris-Sud, UMR-S981, Villejuif, France

2. Gustave Roussy, DHU TORINO, Villejuif, France

3. INSERM, U981, Villejuif, France

4. Princess Margaret Cancer Centre, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada

5. Quinten, Paris, France

6. Département Thoracique, Institut Mutualiste Montsouris, Paris, France

7. Département d'Anatomie Pathologique, Institut Mutualiste Montsouris, Paris, France

Publisher

IOS Press

Subject

Cancer Research,Genetics,Oncology,General Medicine